An orally bioavailable, potent, and selective EP4 receptor antagonist (IC50 = 16.3 nM in a human EP4 functional assay); selective for EP4, with IC50 values of 2.4, 1,890, >20,000, and >20,000 nM for binding to human EP4, EP2, EP1, and EP3, respectively; has potent binding affinity for human, rat, and dog EP4 (Kis = 0.97, 6.1, and 38 nM, respectively; suppresses PGE2-induced elevation of intracellular cAMP in vitro (pA2 = 1.1 nM); reduces carrageenan-induced mechanical hyperalgesia in rats in a dose-dependent manner,